Are we over-treating with checkpoint inhibitors?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Are we over-treating with checkpoint inhibitors?

Published:2019-09-17 Issue:8 Volume:121 Page:629-630
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Danson Sarah,Hook Jane,Marshall Helen,Smith Alexandra,Bell Sue,Rodwell Simon,Corrie Pippa

Funder

DH | NIHR | Health Technology Assessment Programme

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0570-y.pdf

Reference10 articles.

1. da Veiga, C. R. P., da Veiga, C. P. & Drummond-Lage, A. P. Concern over cost of and access to cancer treatments: a meta-narrative review of nivolumab and pembrolizumab studies. Crit. Rev. Oncol. Hematol. 129, 133–145 (2018).

2. Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R. et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann. Oncol. 30, 582–588 (2019).

3. Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).

4. Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).

5. Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M. et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J. Clin. Oncol. 36, 1668–1674 (2018).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition;British Journal of Cancer;2024-06-17

2. Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma;Annals of Hematology;2024-05-11

3. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401;Journal of Clinical Oncology;2023-08-10

4. Organizational Impact of Immunotherapies in Advanced Cancers in France;JCO Global Oncology;2023-08

5. Transition of the PD‑1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re‑challenge;Molecular and Clinical Oncology;2022-04-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3